Clinical Trial Evaluates L-oxiracetam for Cognitive Improvement in Traumatic Brain Injury Patients
A recent multicenter, randomized, double-blind, phase 3 clinical trial, known as the L-oxiracetam Outcomes in Clinical Assessment of Traumatic Brain Injury Effects (LOCATE) trial, has been conducted to evaluate the efficacy and safety of L-oxiracetam on cognitive function in patients with traumatic brain injury (TBI). The trial included participants aged 18 to 75 who had suffered mild to moderate head injuries. Participants were randomly assigned to receive either L-oxiracetam, oxiracetam, or a placebo for 14 days. The primary outcome measured was the change in cognitive function from baseline to 90 days post-treatment, assessed using the LOTCA score. Secondary outcomes included changes in other cognitive assessments and neurological function. The trial aimed to determine whether L-oxiracetam could significantly improve cognitive outcomes compared to placebo. 
